BARDA Web Announcements and Media

BARDA and AVITA Medical partner to secure RECELL Devices for national preparedness

WEB ANNOUNCEMENTS

April 01, 2024

BARDA and AVITA Medical partner to secure RECELL Devices for national preparedness

BARDA announces the 87th FDA Approval, Licensure or Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

WEB ANNOUNCEMENTS

April 01, 2024

BARDA announces the 87th FDA Approval, Licensure or Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

BLOGS/STORIES

March 25, 2024

Building Innovative Platforms

Under Project BioShield contract, BARDA procures additional doses of antibiotic NUZYRA from Paratek Pharmaceuticals

WEB ANNOUNCEMENTS

March 05, 2024

Under Project BioShield contract, BARDA procures additional doses of antibiotic NUZYRA from Paratek Pharmaceuticals

Bolstering biopharmaceutical manufacturing in the U.S. is essential to health preparedness

BLOGS/STORIES

February 22, 2024

Bolstering biopharmaceutical manufacturing in the U.S. is essential to health preparedness

BARDA partners with BioFire Defense to develop improved influenza diagnostic

WEB ANNOUNCEMENTS

February 15, 2024

BARDA partners with BioFire Defense to develop improved influenza diagnostic

BARDA Announces New Project NextGen Partnership Opportunity to Accelerate Retail Clinic and Pharmacy Vaccine Decentralized Clinical Trial Solutions

WEB ANNOUNCEMENTS

February 15, 2024

BARDA Announces New Project NextGen Partnership Opportunity to Accelerate Retail Clinic and Pharmacy Vaccine Decentralized Clinical Trial Solutions

Now Accepting Submissions from Botulinum Neurotoxin Therapeutic Product Developers for Preclinical Testing Services

WEB ANNOUNCEMENTS

February 09, 2024

Now Accepting Submissions from Botulinum Neurotoxin Therapeutic Product Developers for Preclinical Testing Services

BARDA announces clinical studies of host-based diagnostics to demonstrate impact in improving patient care

WEB ANNOUNCEMENTS

February 06, 2024

BARDA announces clinical studies of host-based diagnostics to demonstrate impact in improving patient care

BARDA DRIVe advances ECMO, alternative oxygen delivery methods

WEB ANNOUNCEMENTS

January 23, 2024

BARDA DRIVe advances ECMO, alternative oxygen delivery methods

Advancing U.S. influenza vaccine manufacturing builds readiness for public health emergencies and seasonal vaccine campaigns

BLOGS/STORIES

January 23, 2024

Advancing U.S. influenza vaccine manufacturing builds readiness for public health emergencies and seasonal vaccine campaigns

BARDA announces new partnerships to treat serious outcomes of infectious disease

WEB ANNOUNCEMENTS

January 11, 2024

BARDA announces new partnerships to treat serious outcomes of infectious disease

BARDA selects management firm for new Biopharmaceutical Manufacturing Preparedness Consortium

WEB ANNOUNCEMENTS

January 04, 2024

BARDA selects management firm for new Biopharmaceutical Manufacturing Preparedness Consortium

BARDA and the European Commission’s Health Emergency Preparedness and Response Authority (HERA) Collaborate to Advance Metagenomic Sequencing Diagnostics for Novel Pathogens

WEB ANNOUNCEMENTS

December 27, 2023

BARDA and the European Commission’s Health Emergency Preparedness and Response Authority (HERA) Collaborate to Advance Metagenomic Sequencing Diagnostics for Novel Pathogens

BARDA DRIVe and CBRN Advance Distributed Manufacturing Capabilities for Producing Vaccines at the Point-of-Care

WEB ANNOUNCEMENTS

December 22, 2023

BARDA DRIVe and CBRN Advance Distributed Manufacturing Capabilities for Producing Vaccines at the Point-of-Care

BARDA-Supported Rapid Anthrax Test Receives FDA Clearance

WEB ANNOUNCEMENTS

December 22, 2023

BARDA-Supported Rapid Anthrax Test Receives FDA Clearance

BARDA Awards $117 Million for First Clinical Trial for New Acute Respiratory Distress Syndrome Treatments

WEB ANNOUNCEMENTS

December 21, 2023

BARDA Awards $117 Million for First Clinical Trial for New Acute Respiratory Distress Syndrome Treatments

BARDA supports an FDA-approved opioid overdose rescue medication from Indivior Inc towards a pediatric indication and procures adult doses for national preparedness

WEB ANNOUNCEMENTS

December 20, 2023

BARDA supports an FDA-approved opioid overdose rescue medication from Indivior Inc towards a pediatric indication and procures adult doses for national preparedness

Rapid Hematology Analysis Platform Becomes Latest BARDA-Supported Medical Countermeasure to Receive FDA Clearance

WEB ANNOUNCEMENTS

December 18, 2023

Rapid Hematology Analysis Platform Becomes Latest BARDA-Supported Medical Countermeasure to Receive FDA Clearance

In 2023, BARDA advanced its capacity to stay at the forefront of health security and innovation

BLOGS/STORIES

December 15, 2023

In 2023, BARDA advanced its capacity to stay at the forefront of health security and innovation

BARDA and Spectral MD partner on the development of the DeepView Burn Imaging System to elevate burn care

WEB ANNOUNCEMENTS

December 12, 2023

BARDA and Spectral MD partner on the development of the DeepView Burn Imaging System to elevate burn care

BARDA partners with the Wyss Institute at Harvard University to advance medical countermeasure development; organ; chip-based

WEB ANNOUNCEMENTS

November 28, 2023

BARDA partners with the Wyss Institute at Harvard University to advance medical countermeasure development; organ; chip-based

WATCH THE VIDEOS: BARDA Industry Day 2023

EVENTS/MEETINGS

November 13, 2023

WATCH THE VIDEOS: BARDA Industry Day 2023

FDA provides Emergency Use Authorization of 3EO Health COVID-19 Test developed with BARDA support

WEB ANNOUNCEMENTS

November 09, 2023

FDA provides Emergency Use Authorization of 3EO Health COVID-19 Test developed with BARDA support

BARDA and Rafa Laboratories collaborate to advance development of pediatric atropine autoinjectors and boost national preparedness

WEB ANNOUNCEMENTS

November 07, 2023

BARDA and Rafa Laboratories collaborate to advance development of pediatric atropine autoinjectors and boost national preparedness

BARDA-Supported Molecular Diagnostic Test for Six Biothreat Pathogens Receives FDA-Clearance

WEB ANNOUNCEMENTS

October 31, 2023

BARDA-Supported Molecular Diagnostic Test for Six Biothreat Pathogens Receives FDA-Clearance

BARDA secures additional doses of Ebola virus vaccine from Merck

WEB ANNOUNCEMENTS

October 26, 2023

BARDA secures additional doses of Ebola virus vaccine from Merck

BARDA partners with Hoxworth Blood Center to develop and validate an improved method to evaluate next-generation blood products.

WEB ANNOUNCEMENTS

October 25, 2023

BARDA partners with Hoxworth Blood Center to develop and validate an improved method to evaluate next-generation blood products.

BARDA procures additional Nplate doses, supports development of kit for faster, easier treatment administration to counter acute radiation syndrome

WEB ANNOUNCEMENTS

October 24, 2023

BARDA procures additional Nplate doses, supports development of kit for faster, easier treatment administration to counter acute radiation syndrome

BARDA partners with Advanced Technology International to manage new Rapid Response Partnership Vehicle consortium

WEB ANNOUNCEMENTS

October 20, 2023

BARDA partners with Advanced Technology International to manage new Rapid Response Partnership Vehicle consortium

Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics

WEB ANNOUNCEMENTS

October 13, 2023

Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics

BARDA collaborates with GE HealthCare to develop a novel AI-augmented ultrasound technology to expand national capabilities to aid rapid diagnosis of traumatic injuries

WEB ANNOUNCEMENTS

October 11, 2023

BARDA collaborates with GE HealthCare to develop a novel AI-augmented ultrasound technology to expand national capabilities to aid rapid diagnosis of traumatic injuries

Innovative diagnostic technologies advance everyday care and public health preparedness

BLOGS/STORIES

October 11, 2023

Innovative diagnostic technologies advance everyday care and public health preparedness

BARDA expands partnership with Venatorx Pharmaceuticals to advance an oral antibiotic to treat drug-resistant gram-negative bacterial infections

WEB ANNOUNCEMENTS

October 10, 2023

BARDA expands partnership with Venatorx Pharmaceuticals to advance an oral antibiotic to treat drug-resistant gram-negative bacterial infections

BARDA and Eitr Biologics partner to develop a therapeutic platform to address viral threats

WEB ANNOUNCEMENTS

September 27, 2023

BARDA and Eitr Biologics partner to develop a therapeutic platform to address viral threats

BARDA releases new Broad Agency Announcement (BAA) to speed medical countermeasure development

WEB ANNOUNCEMENTS

September 26, 2023

BARDA releases new Broad Agency Announcement (BAA) to speed medical countermeasure development

BARDA and the University of Pittsburgh collaborate on a clinical trial to identify optimal transfusion practices in pediatric patients

WEB ANNOUNCEMENTS

September 21, 2023

BARDA and the University of Pittsburgh collaborate on a clinical trial to identify optimal transfusion practices in pediatric patients

BARDA Continues Partnership with Sabin Vaccine Institute to Advance Development and Manufacturing of Two Filovirus Vaccines

WEB ANNOUNCEMENTS

September 14, 2023

BARDA Continues Partnership with Sabin Vaccine Institute to Advance Development and Manufacturing of Two Filovirus Vaccines

BARDA-Supported Multiplex Diagnostic Test for COVID-19, Flu, and RSV Receives FDA-Clearance

WEB ANNOUNCEMENTS

September 07, 2023

BARDA-Supported Multiplex Diagnostic Test for COVID-19, Flu, and RSV Receives FDA-Clearance

BARDA partners with Cue Health to develop a multiplex test to detect and differentiate influenza, RSV, and SARS-CoV-2

WEB ANNOUNCEMENTS

August 28, 2023

BARDA partners with Cue Health to develop a multiplex test to detect and differentiate influenza, RSV, and SARS-CoV-2

Project NextGen Awards Over $1.4 Billion to Develop the Future of COVID-19 Vaccines and Therapeutics

WEB ANNOUNCEMENTS

August 24, 2023

Project NextGen Awards Over $1.4 Billion to Develop the Future of COVID-19 Vaccines and Therapeutics

Year Two of the BARDA Ventures-GHIC Partnership: Boosting Medical Countermeasure Innovation

BLOGS/STORIES

August 24, 2023

Year Two of the BARDA Ventures-GHIC Partnership: Boosting Medical Countermeasure Innovation

Ebola vaccine for children becomes 81st FDA Approval of BARDA-supported Medical Countermeasures

WEB ANNOUNCEMENTS

August 18, 2023

Ebola vaccine for children becomes 81st FDA Approval of BARDA-supported Medical Countermeasures

BARDA continues partnership with Emergent BioSolutions to support manufacturing of a licensed therapeutic for Ebola virus disease

WEB ANNOUNCEMENTS

August 09, 2023

BARDA continues partnership with Emergent BioSolutions to support manufacturing of a licensed therapeutic for Ebola virus disease

BARDA-Supported Anthrax Vaccine Now Approved, Enables Faster Onset...

WEB ANNOUNCEMENTS

August 07, 2023

BARDA-Supported Anthrax Vaccine Now Approved, Enables Faster Onset...

BARDA seeks Consortium Management Firm to establish new Biopharmaceutical Manufacturing Preparedness Consortium aimed at expanding domestic vaccine and drug manufacturing capability

WEB ANNOUNCEMENTS

August 04, 2023

BARDA seeks Consortium Management Firm to establish new Biopharmaceutical Manufacturing Preparedness Consortium aimed at expanding domestic vaccine and drug manufacturing capability

Collaborating to identify challenges and solutions for NGS-based agnostic diagnostic technologies

BLOGS/STORIES

August 02, 2023

Collaborating to identify challenges and solutions for NGS-based agnostic diagnostic technologies

Handheld Influenza Test Specimen Collection Device Becomes Latest FDA-Cleared Medical Countermeasure with BARDA Support

WEB ANNOUNCEMENTS

July 31, 2023

Handheld Influenza Test Specimen Collection Device Becomes Latest FDA-Cleared Medical Countermeasure with BARDA Support

BARDA and Isola Therapeutics partner to repurpose a lung cancer procedure as a medical countermeasure against inhaled phosgene exposure

WEB ANNOUNCEMENTS

July 26, 2023

BARDA and Isola Therapeutics partner to repurpose a lung cancer procedure as a medical countermeasure against inhaled phosgene exposure

Project NextGen: Enablers for Innovative COVID-19 Vaccine Manufacturing Virtual Event

EVENTS/MEETINGS

July 20, 2023

Project NextGen: Enablers for Innovative COVID-19 Vaccine Manufacturing Virtual Event

Treatment for full thickness skin defects becomes 78th FDA approval for a BARDA-supported product

WEB ANNOUNCEMENTS

July 12, 2023

Treatment for full thickness skin defects becomes 78th FDA approval for a BARDA-supported product

BARDA partners with Melinta Therapeutics to advance two FDA-approved antibiotics

WEB ANNOUNCEMENTS

July 10, 2023

BARDA partners with Melinta Therapeutics to advance two FDA-approved antibiotics

BARDA seeks Consortium Management Firm to run new Rapid Response Partnership Vehicle

WEB ANNOUNCEMENTS

July 10, 2023

BARDA seeks Consortium Management Firm to run new Rapid Response Partnership Vehicle

BARDA to host a Project NextGen workshop to engage with the vaccine development and manufacturing communities

WEB ANNOUNCEMENTS

July 07, 2023

BARDA to host a Project NextGen workshop to engage with the vaccine development and manufacturing communities

BARDA launches the D-COHRe program, seeking to enhance clinical innovation with decentralized care capabilities

WEB ANNOUNCEMENTS

July 05, 2023

BARDA launches the D-COHRe program, seeking to enhance clinical innovation with decentralized care capabilities

BARDA partners with ARIScience to accelerate screening for respiratory stimulant candidates for opioid overdoses

WEB ANNOUNCEMENTS

June 26, 2023

BARDA partners with ARIScience to accelerate screening for respiratory stimulant candidates for opioid overdoses

Flexible and sustainable products are core elements of health emergency preparedness

BLOGS/STORIES

June 22, 2023

Flexible and sustainable products are core elements of health emergency preparedness

BARDA seeks submissions for the development of advanced microphysiological immune tissue platforms through the DRIVe ImmuneChip+ program

WEB ANNOUNCEMENTS

June 21, 2023

BARDA seeks submissions for the development of advanced microphysiological immune tissue platforms through the DRIVe ImmuneChip+ program

Addressing Traumatic Injuries to Bolster National Preparedness and Response

BLOGS/STORIES

June 12, 2023

Addressing Traumatic Injuries to Bolster National Preparedness and Response

BARDA announces the 77th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel-Public Private Partnerships

WEB ANNOUNCEMENTS

June 09, 2023

BARDA announces the 77th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel-Public Private Partnerships

BARDA statement on the FDA marketing authorization for the Cue COVID-19 Molecular Test

WEB ANNOUNCEMENTS

June 09, 2023

BARDA statement on the FDA marketing authorization for the Cue COVID-19 Molecular Test

BARDA announces the 74th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel-Public Private Partnerships

WEB ANNOUNCEMENTS

June 08, 2023

BARDA announces the 74th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel-Public Private Partnerships

BARDA announces the 75th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

WEB ANNOUNCEMENTS

June 08, 2023

BARDA announces the 75th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

BARDA Announces New FDA Approval for Medical Countermeasures Supported by BARDA Under Novel-Public Private Partnerships

WEB ANNOUNCEMENTS

June 02, 2023

BARDA Announces New FDA Approval for Medical Countermeasures Supported by BARDA Under Novel-Public Private Partnerships

BARDA supports advanced research and development efforts for medical countermeasures under Project NextGen

WEB ANNOUNCEMENTS

May 26, 2023

BARDA supports advanced research and development efforts for medical countermeasures under Project NextGen

BARDA announces the 72nd and 73rd FDA approvals/licensures/clearances for medical countermeasures supported by BARDA under novel public-private partnerships

WEB ANNOUNCEMENTS

May 23, 2023

BARDA announces the 72nd and 73rd FDA approvals/licensures/clearances for medical countermeasures supported by BARDA under novel public-private partnerships

BLOGS/STORIES

May 22, 2023

Advancing Inclusion in Clinical Trials

BARDA will host a live Q&A for potential offerors about our open FASTx BAA and EZ-BAA solicitations for the development of therapeutic platforms for the treatment of acute viral infections

EVENTS/MEETINGS

May 19, 2023

BARDA will host a live Q&A for potential offerors about our open FASTx BAA and EZ-BAA solicitations for the development of therapeutic platforms for the treatment of acute viral infections

BARDA announces the 71st FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

WEB ANNOUNCEMENTS

May 18, 2023

BARDA announces the 71st FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

WEB ANNOUNCEMENTS

May 18, 2023

BARDA announces the 71st FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public-Private Partnerships

BARDA will host a live Q&A webinar for vaccine developers interested in our COVID-19 area of interest

EVENTS/MEETINGS

May 17, 2023

BARDA will host a live Q&A webinar for vaccine developers interested in our COVID-19 area of interest

BARDA Support Protects Against Drug-Resistant Threats

BLOGS/STORIES

April 27, 2023

BARDA Support Protects Against Drug-Resistant Threats

BARDA partners with Aptitude to accelerate development and clearance of at-home SARS-CoV-2 and influenza tests

WEB ANNOUNCEMENTS

April 20, 2023

BARDA partners with Aptitude to accelerate development and clearance of at-home SARS-CoV-2 and influenza tests

Just Breathe - An ARDS Therapeutics Pitch Event

EVENTS/MEETINGS

April 18, 2023

Just Breathe - An ARDS Therapeutics Pitch Event

WEB ANNOUNCEMENTS

April 18, 2023

BARDA will host Just Breathe – An ARDS Therapeutics Pitch Event (July 24-28, 2023) to address acute respiratory distress syndrome (ARDS)

Health-at-home technologies empowers patients and clinicians

BLOGS/STORIES

April 10, 2023

Health-at-home technologies empowers patients and clinicians

BARDA announces the 70th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

WEB ANNOUNCEMENTS

March 30, 2023

BARDA announces the 70th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

BARDA announces the 69th FDA approval/licensure/clearance for medical countermeasures supported by BARDA under novel public-private partnerships

WEB ANNOUNCEMENTS

March 28, 2023

BARDA announces the 69th FDA approval/licensure/clearance for medical countermeasures supported by BARDA under novel public-private partnerships

BARDA announces the 68th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

WEB ANNOUNCEMENTS

February 27, 2023

BARDA announces the 68th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

FDA provides Emergency Use Authorization of Becton, Dickinson and Company’s BD Respiratory Viral Panel for BD MAX System developed in collaboration with BARDA

WEB ANNOUNCEMENTS

February 27, 2023

FDA provides Emergency Use Authorization of Becton, Dickinson and Company’s BD Respiratory Viral Panel for BD MAX System developed in collaboration with BARDA

BARDA announces the 67th FDA approval/licensure/clearance for medical countermeasures supported by BARDA under novel public-private partnerships

WEB ANNOUNCEMENTS

February 23, 2023

BARDA announces the 67th FDA approval/licensure/clearance for medical countermeasures supported by BARDA under novel public-private partnerships

VIDEOS

February 15, 2023

2023 FEDERAL HEALTH-AT-HOME TECHNOLOGY SUMMIT

BARDA announces two EZ-BAA partnerships to develop technologies for rapid and multiplexed at-home blood testing

WEB ANNOUNCEMENTS

February 07, 2023

BARDA announces two EZ-BAA partnerships to develop technologies for rapid and multiplexed at-home blood testing

BARDA announces the 66th FDA Approval for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

WEB ANNOUNCEMENTS

February 07, 2023

BARDA announces the 66th FDA Approval for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

BARDA launches RePAIR program, seeking innovative approaches to repurpose therapeutics for radiological and nuclear incidents

WEB ANNOUNCEMENTS

February 01, 2023

BARDA launches RePAIR program, seeking innovative approaches to repurpose therapeutics for radiological and nuclear incidents

BARDA seeks proposals for implementing a phase 2 platform clinical trial to investigate host-directed therapies for acute respiratory distress syndrome

WEB ANNOUNCEMENTS

January 31, 2023

BARDA seeks proposals for implementing a phase 2 platform clinical trial to investigate host-directed therapies for acute respiratory distress syndrome

2023: Building on preparedness, response, and partnership to stay at the forefront of health security

BLOGS/STORIES

January 31, 2023

2023: Building on preparedness, response, and partnership to stay at the forefront of health security

BARDA and BioFire Defense, LLC accelerate development of the Specific Diagnostics SPECIFIC Reveal Rapid AST System to aid in treating bacterial infections

WEB ANNOUNCEMENTS

January 30, 2023

BARDA and BioFire Defense, LLC accelerate development of the Specific Diagnostics SPECIFIC Reveal Rapid AST System to aid in treating bacterial infections

BARDA announces new partnerships to develop at-home diagnostic technologies for COVID-19, influenza, and future pandemic preparedness

WEB ANNOUNCEMENTS

January 26, 2023

BARDA announces new partnerships to develop at-home diagnostic technologies for COVID-19, influenza, and future pandemic preparedness

BARDA seeks abstract submissions for medical countermeasure development through the expanded DRIVe ReDIRECT Program

WEB ANNOUNCEMENTS

January 19, 2023

BARDA seeks abstract submissions for medical countermeasure development through the expanded DRIVe ReDIRECT Program

Emergency Use Authorization granted for BARDA-supported Diazyme Laboratories, Inc. SARS-CoV-2 Neutralizing Antibody CLIA Kit

WEB ANNOUNCEMENTS

January 18, 2023

Emergency Use Authorization granted for BARDA-supported Diazyme Laboratories, Inc. SARS-CoV-2 Neutralizing Antibody CLIA Kit

BARDA and Visby Medical Inc. partnership results in Emergency Use Authorization (EUA) of a rapid, hand-held, RT-PCR based influenza A/B and COVID-19 multiplex test for point-of-care use

WEB ANNOUNCEMENTS

January 13, 2023

BARDA and Visby Medical Inc. partnership results in Emergency Use Authorization (EUA) of a rapid, hand-held, RT-PCR based influenza A/B and COVID-19 multiplex test for point-of-care use

BARDA supports Sabin Vaccine Institute manufacturing of additional clinical doses of Ebolavirus vaccines

WEB ANNOUNCEMENTS

January 12, 2023

BARDA supports Sabin Vaccine Institute manufacturing of additional clinical doses of Ebolavirus vaccines

BARDA announces the 65th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

WEB ANNOUNCEMENTS

December 22, 2022

BARDA announces the 65th FDA Approval/Licensure/Clearance for Medical Countermeasures supported by BARDA under Novel Public Private Partnerships

BARDA partners with multiple companies for early development of novel host-directed COVID-19 treatments

WEB ANNOUNCEMENTS

December 09, 2022

BARDA partners with multiple companies for early development of novel host-directed COVID-19 treatments

BARDA continues to catalyze solutions for sepsis with partnerships with Patchd and Endpoint Health

WEB ANNOUNCEMENTS

November 23, 2022

BARDA continues to catalyze solutions for sepsis with partnerships with Patchd and Endpoint Health

BARDA makes support available for development of novel antifungals to boost national preparedness

WEB ANNOUNCEMENTS

November 18, 2022

BARDA makes support available for development of novel antifungals to boost national preparedness

EVENTS/MEETINGS

November 15, 2022

WATCH VIDEOS - BARDA Industry Day 2022

Winning Designs Selected in Mask Innovation Challenge

BLOGS/STORIES

November 15, 2022

Winning Designs Selected in Mask Innovation Challenge

BARDA supports development of novel AI/ML-based digital apps for visual and auditory symptomatic infectious disease detection

WEB ANNOUNCEMENTS

November 09, 2022

BARDA supports development of novel AI/ML-based digital apps for visual and auditory symptomatic infectious disease detection

WEB ANNOUNCEMENTS

November 09, 2022

BARDA launches new iteration of the DRIVe EZ-BAA, with a new + Phase and new areas of interest

BARDA launches ReBooT program, seeking innovative approaches to repurpose antiviral drugs to address filoviruses

WEB ANNOUNCEMENTS

November 01, 2022

BARDA launches ReBooT program, seeking innovative approaches to repurpose antiviral drugs to address filoviruses

BARDA supports advanced development of a test from BioFire Defense, LLC to detect six biothreat pathogens

WEB ANNOUNCEMENTS

October 20, 2022

BARDA supports advanced development of a test from BioFire Defense, LLC to detect six biothreat pathogens

BARDA and Vir Biotechnology collaborate to advance development of a therapeutic for pre-exposure prophylaxis for Influenza A

WEB ANNOUNCEMENTS

October 20, 2022

BARDA and Vir Biotechnology collaborate to advance development of a therapeutic for pre-exposure prophylaxis for Influenza A

BARDA and OraSure Technologies, Inc. partner to develop a second-generation version of the FDA De Novo-cleared OraQuick Ebola Rapid Antigen Test

WEB ANNOUNCEMENTS

October 19, 2022

BARDA and OraSure Technologies, Inc. partner to develop a second-generation version of the FDA De Novo-cleared OraQuick Ebola Rapid Antigen Test

BARDA & DiaSorin Molecular, LLC partner to develop and achieve regulatory clearance of a combined SARS-CoV-2, influenza A & B test on the LIAISON NES system

WEB ANNOUNCEMENTS

October 18, 2022

BARDA & DiaSorin Molecular, LLC partner to develop and achieve regulatory clearance of a combined SARS-CoV-2, influenza A & B test on the LIAISON NES system

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

WEB ANNOUNCEMENTS

October 18, 2022

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

BARDA and BioFire Defense, LLC partner to develop molecular panel to detect known, novel, and emerging human coronaviruses

WEB ANNOUNCEMENTS

October 13, 2022

BARDA and BioFire Defense, LLC partner to develop molecular panel to detect known, novel, and emerging human coronaviruses

BARDA continues biodosimetry partnership with ASELL through agreement to develop triage diagnostic for initial evaluation of radiation exposure

WEB ANNOUNCEMENTS

October 06, 2022

BARDA continues biodosimetry partnership with ASELL through agreement to develop triage diagnostic for initial evaluation of radiation exposure

BARDA partners with Clinical Studies Network (CSN) Contractors, ICON and Rho

WEB ANNOUNCEMENTS

October 06, 2022

BARDA partners with Clinical Studies Network (CSN) Contractors, ICON and Rho

BARDA partners with GSK and CSL Seqirus to manufacture and assess the safety, immunogenicity of pandemic influenza vaccine candidates

WEB ANNOUNCEMENTS

October 06, 2022

BARDA partners with GSK and CSL Seqirus to manufacture and assess the safety, immunogenicity of pandemic influenza vaccine candidates

BARDA and Enalare Therapeutics further partnership to advance ENA-001 as an emergency treatment for opioid-induced respiratory depression

WEB ANNOUNCEMENTS

October 05, 2022

BARDA and Enalare Therapeutics further partnership to advance ENA-001 as an emergency treatment for opioid-induced respiratory depression

BARDA partners with Diazyme Laboratories, Inc. to develop a rapid high-throughput assay that measures the neutralizing effect of SARS-CoV-2 antibodies

WEB ANNOUNCEMENTS

October 04, 2022

BARDA partners with Diazyme Laboratories, Inc. to develop a rapid high-throughput assay that measures the neutralizing effect of SARS-CoV-2 antibodies

HHS purchases drug for use in radiological and nuclear emergencies

WEB ANNOUNCEMENTS

October 04, 2022

HHS purchases drug for use in radiological and nuclear emergencies

HHS funds development, purchase of antidote-filled autoinjectors for rapid chemical terrorism response

WEB ANNOUNCEMENTS

October 03, 2022

HHS funds development, purchase of antidote-filled autoinjectors for rapid chemical terrorism response

HHS expands nationwide skin donation inventory available for burn injuries in mass casualty incidents

WEB ANNOUNCEMENTS

October 03, 2022

HHS expands nationwide skin donation inventory available for burn injuries in mass casualty incidents

ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus

WEB ANNOUNCEMENTS

September 30, 2022

ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus

BARDA partners with the Johns Hopkins University Applied Physics Laboratory to develop a resource-tracking and communication application

WEB ANNOUNCEMENTS

September 23, 2022

BARDA partners with the Johns Hopkins University Applied Physics Laboratory to develop a resource-tracking and communication application

BARDA partners with Abbott to develop expanded capabilities and indication for TBI blood test to aid in diagnosing severity in adults and children

WEB ANNOUNCEMENTS

September 22, 2022

BARDA partners with Abbott to develop expanded capabilities and indication for TBI blood test to aid in diagnosing severity in adults and children

BARDA announces the 64th FDA Approval/Licensure/Clearance for Simplexa™ COVID-19 Direct

WEB ANNOUNCEMENTS

September 22, 2022

BARDA announces the 64th FDA Approval/Licensure/Clearance for Simplexa™ COVID-19 Direct

Investing for Health Security: The First Year of BARDA Ventures

BLOGS/STORIES

September 22, 2022

Investing for Health Security: The First Year of BARDA Ventures

BARDA and Arcturus Therapeutics Holdings, Inc. partner to develop a self-amplifying mRNA-based vaccine for rapid pandemic influenza response

WEB ANNOUNCEMENTS

August 31, 2022

BARDA and Arcturus Therapeutics Holdings, Inc. partner to develop a self-amplifying mRNA-based vaccine for rapid pandemic influenza response

BARDA requests input on its vision for new Rapid Response Partnership Vehicle, the next generation in health security acquisitions

WEB ANNOUNCEMENTS

August 30, 2022

BARDA requests input on its vision for new Rapid Response Partnership Vehicle, the next generation in health security acquisitions

BARDA and Chimerix, Inc. partner under Project BioShield to procure TEMBEXA, a second licensed therapeutic for smallpox

WEB ANNOUNCEMENTS

August 29, 2022

BARDA and Chimerix, Inc. partner under Project BioShield to procure TEMBEXA, a second licensed therapeutic for smallpox

BARDA procures additional doses of intravenous TPOXX for national preparedness

WEB ANNOUNCEMENTS

August 22, 2022

BARDA procures additional doses of intravenous TPOXX for national preparedness

VIDEOS

August 08, 2022

BARDA Director Gary L. Disbrow, Ph.D., Joins Rich Bendis on the BioTalk Podcast

News Release from HHS.gov: Biden-Harris Administration Secures 66 Million Doses of Moderna’s Variant-Specific COVID-19 Vaccine Booster for Potential Use in Fall and Winter 2022

WEB ANNOUNCEMENTS

July 29, 2022

News Release from HHS.gov: Biden-Harris Administration Secures 66 Million Doses of Moderna’s Variant-Specific COVID-19 Vaccine Booster for Potential Use in Fall and Winter 2022

DRIVe seeks abstract submissions for innovative technologies to improve lung support for severe acute respiratory distress syndrome (ARDS) patients

WEB ANNOUNCEMENTS

July 19, 2022

DRIVe seeks abstract submissions for innovative technologies to improve lung support for severe acute respiratory distress syndrome (ARDS) patients

News Release from HHS.gov: HHS orders additional vaccine, increases testing capacity to respond to mpox outbreak

WEB ANNOUNCEMENTS

July 15, 2022

News Release from HHS.gov: HHS orders additional vaccine, increases testing capacity to respond to mpox outbreak

News Release from HHS.gov: Biden-Harris Administration secures 3.2 million doses of Novavax COVID-19 Vaccine

WEB ANNOUNCEMENTS

July 11, 2022

News Release from HHS.gov: Biden-Harris Administration secures 3.2 million doses of Novavax COVID-19 Vaccine

News Release from HHS.gov: Biden-Harris Administration to make an additional 144,000 doses of JYNNEOS vaccine available to states and jurisdictions for mpox response

WEB ANNOUNCEMENTS

July 07, 2022

News Release from HHS.gov: Biden-Harris Administration to make an additional 144,000 doses of JYNNEOS vaccine available to states and jurisdictions for mpox response

News Release from HHS.gov: HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine for Mpox Preparedness

WEB ANNOUNCEMENTS

July 01, 2022

News Release from HHS.gov: HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine for Mpox Preparedness

BARDA and Crossject partner under Project BioShield to provide novel needle-free ZENEO Midazolam autoinjectors for national preparedness

WEB ANNOUNCEMENTS

June 30, 2022

BARDA and Crossject partner under Project BioShield to provide novel needle-free ZENEO Midazolam autoinjectors for national preparedness

WEB ANNOUNCEMENTS

June 30, 2022

Addressing Antimicrobial Resistance

Biden-Harris Administration Purchases Additional Doses of Bebtelovimab to Treat High-risk COVID-19 Patients

WEB ANNOUNCEMENTS

June 29, 2022

Biden-Harris Administration Purchases Additional Doses of Bebtelovimab to Treat High-risk COVID-19 Patients

News Release from HHS.gov: Biden-Harris Administration secures 105 million doses of Pfizer’s latest COVID-19 vaccine for fall vaccination campaign

WEB ANNOUNCEMENTS

June 29, 2022

News Release from HHS.gov: Biden-Harris Administration secures 105 million doses of Pfizer’s latest COVID-19 vaccine for fall vaccination campaign

WEB ANNOUNCEMENTS

June 17, 2022

Save the Date – BARDA Industry Day 2022

VIDEOS

June 16, 2022

How CARB-X is Addressing AMR

VIDEOS

June 09, 2022

Antimicrobial Resistance: CARB-X Partners Addressing a Global Health Threat - Virtual Webinar

BARDA’s Preparedness Investments Enabled Rapid Response to U.S. Mpox Outbreak

BLOGS/STORIES

June 08, 2022

BARDA’s Preparedness Investments Enabled Rapid Response to U.S. Mpox Outbreak

BARDA Announces Phase 2 Finalists of the Mask Innovation Challenge

BLOGS/STORIES

June 06, 2022

BARDA Announces Phase 2 Finalists of the Mask Innovation Challenge

WEB ANNOUNCEMENTS

May 24, 2022

BARDA's Strategic Plan 2022-2026

VIDEOS

May 24, 2022

BARDA Strategy 2022-2026, Fortifying the Nation's Health Security: BARDA Director Introduction

News Release from HHS.gov: HHS commits up to $300 million over 10 years to combat antibiotic-resistant bacteria

WEB ANNOUNCEMENTS

May 19, 2022

News Release from HHS.gov: HHS commits up to $300 million over 10 years to combat antibiotic-resistant bacteria

Unlocking Insights from Real-World Data to Help Pediatric COVID-19 Patients

BLOGS/STORIES

April 06, 2022

Unlocking Insights from Real-World Data to Help Pediatric COVID-19 Patients

2022 NEXT-GEN FILOVIRUS THERAPEUTICS WORKSHOP - March 9, 2022

EVENTS/MEETINGS

March 09, 2022

2022 NEXT-GEN FILOVIRUS THERAPEUTICS WORKSHOP - March 9, 2022

HHS News Release: Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron

WEB ANNOUNCEMENTS

February 15, 2022

HHS News Release: Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron

BLOGS/STORIES

February 01, 2022

BARDA’s First 15 Years

EVENTS/MEETINGS

January 26, 2022

2022 Filovirus Vaccine Development Workshop - January 26, 2022

EVENTS/MEETINGS

January 20, 2022

BioPharmaceutical Manufacturing Partnership Consortium (BIOMAC) Industry Day - January 20, 2022

The Mask Innovation Challenge Goes From Paper to Prototype

BLOGS/STORIES

December 21, 2021

The Mask Innovation Challenge Goes From Paper to Prototype

BLOGS/STORIES

November 23, 2021

Combatting Antimicrobial Resistance

EVENTS/MEETINGS

November 03, 2021

BARDA Industry Day - November 3-4, 2021

VIDEOS

November 03, 2021

BARDA Industry Day 2021 Presentation Videos

VIDEOS

November 03, 2021

BARDA Industry Day 2022 Presentation Videos

BLOGS/STORIES

October 08, 2021

2021 Federal Wearables Summit

VIDEOS

August 31, 2021

BARDA DRIVe 2021 Federal Wearables Summit: Dr. Gary Disbrow Welcome Remarks

BLOGS/STORIES

August 10, 2021

Correlates of Protection

Learn about BARDA Regulatory & Quality Affairs' role in the COVID-19 response and the differences between a COVID-19 EUA and a traditional FDA approval

BLOGS/STORIES

July 21, 2021

Learn about BARDA Regulatory & Quality Affairs' role in the COVID-19 response and the differences between a COVID-19 EUA and a traditional FDA approval

BARDA-NIOSH Mask Innovation Challenge Selects 10 Winning Concepts for $10,000 Phase 1 Prizes

BLOGS/STORIES

July 02, 2021

BARDA-NIOSH Mask Innovation Challenge Selects 10 Winning Concepts for $10,000 Phase 1 Prizes

Global collaboration with BARDA scientists successfully develop Ebola countermeasures

BLOGS/STORIES

June 21, 2021

Global collaboration with BARDA scientists successfully develop Ebola countermeasures

VIDEOS

May 04, 2021

BARDA Vaccine Market Research Workshop

BARDA Vaccines Against AMR Threats Workshop

EVENTS/MEETINGS

March 12, 2021

BARDA Vaccines Against AMR Threats Workshop

VIDEOS

March 01, 2021

Statement: BARDA director on emergency use authorization of the third COVID-19 vaccine

VIDEOS

February 25, 2021

#ASKBARDA - What are some possible outcomes after the Data Safety Monitoring Board meets?

VIDEOS

February 25, 2021

#ASKBARDA - What is an independent Data Safety Monitoring Board (DSMB)?

VIDEOS

February 25, 2021

#ASKBARDA - Why can't we know if the trial participant received the actual product or the placebo?

VIDEOS

February 25, 2021

#ASKBARDA - When a clinical trial is paused, or stopped, is that planned?

VIDEOS

February 25, 2021

#ASKBARDA - Can you walk us through how clinical trial protocols have safety measures built in?

VIDEOS

February 25, 2021

#ASKBARDA - What does it mean when a clinical trial is paused?

VIDEOS

February 09, 2021

BARDA COVID-19 Response: Dr. Robert Johnson, BARDA IEIDD Division Director and BARDA COVID-19 Response Lead

VIDEOS

December 08, 2020

CARB-X: 2020 Partnership Award

VIDEOS

October 27, 2020

BARDA Industry Day 2020 Presentations

VIDEOS

October 17, 2020

Hear directly from the BARDA CBRN director, Dr. Chris Houchens, on his 2021 priorities. BARDA Industry Day 2020

VIDEOS

October 12, 2020

#MakingCountermeasures Series

EVENTS/MEETINGS

August 01, 2020

BARDA Industry Day 2020

FDA ends emergency use authorization (EUA) of hydroxychloroquine

WEB ANNOUNCEMENTS

June 15, 2020

FDA ends emergency use authorization (EUA) of hydroxychloroquine

HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients

WEB ANNOUNCEMENTS

March 29, 2020

HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients

HHS funds development of COVID-19 diagnostic tests

WEB ANNOUNCEMENTS

March 13, 2020

HHS funds development of COVID-19 diagnostic tests

HHS Supports Development of First High-Throughput COVID-19 Diagnostic Test; SARS-CoV-2; EZ-BAA

WEB ANNOUNCEMENTS

March 10, 2020

HHS Supports Development of First High-Throughput COVID-19 Diagnostic Test; SARS-CoV-2; EZ-BAA

WEB ANNOUNCEMENTS

March 09, 2020

HHS Supports Development of First High-Throughput COVID-19 Diagnostic Test

HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus Vaccine

WEB ANNOUNCEMENTS

February 18, 2020

HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus Vaccine

HHS, Janssen Collaborate To Develop Coronavirus Therapeutics

WEB ANNOUNCEMENTS

February 18, 2020

HHS, Janssen Collaborate To Develop Coronavirus Therapeutics

HHS, Janssen Join Forces On Coronavirus Vaccine

WEB ANNOUNCEMENTS

February 11, 2020

HHS, Janssen Join Forces On Coronavirus Vaccine

HHS Seeks Abstract Submissions for 2019-nCoV Diagnostics Development

WEB ANNOUNCEMENTS

February 05, 2020

HHS Seeks Abstract Submissions for 2019-nCoV Diagnostics Development

HHS, Regeneron Collaborate to Develop 2019-nCoV Treatment

WEB ANNOUNCEMENTS

February 04, 2020

HHS, Regeneron Collaborate to Develop 2019-nCoV Treatment

New Pandemic Influenza Vaccine Uses Next Generation Technology to Strengthen Health Security

WEB ANNOUNCEMENTS

February 03, 2020

New Pandemic Influenza Vaccine Uses Next Generation Technology to Strengthen Health Security

Secretary Azar Declares Public Health Emergency for United States for 2019 Novel Coronavirus

WEB ANNOUNCEMENTS

January 31, 2020

Secretary Azar Declares Public Health Emergency for United States for 2019 Novel Coronavirus

2019 Novel Coronavirus Stakeholder Listening Session

WEB ANNOUNCEMENTS

January 29, 2020

2019 Novel Coronavirus Stakeholder Listening Session

EVENTS/MEETINGS

October 15, 2019

BARDA Industry Day 2019

EVENTS/MEETINGS

October 07, 2015

NIH/BARDA Request for Comment for Antimicrobial Resistance Rapid Point of Care Diagnostic Test

EVENTS/MEETINGS

November 02, 2013

BARDA Broad Agency Announcement Pre-Proposal Conference

EVENTS/MEETINGS

February 10, 2011

5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day

EVENTS/MEETINGS

November 05, 2010

Animal Model Draft Guidance Public Meeting

EVENTS/MEETINGS

December 02, 2009

HHS PHEMCE Stakeholders Workshop 2009 and BARDA Industry Day

EVENTS/MEETINGS

June 25, 2009

CBRN Medical Countermeasures Workshop

EVENTS/MEETINGS

September 24, 2008

HHS PHEMCE Stakeholders Workshop 2008 and BARDA Industry Day

EVENTS/MEETINGS

May 05, 2008

Eleventh Annual Conference on Vaccine Research

EVENTS/MEETINGS

July 31, 2007

HHS PHEMC Enterprise Stakeholders Workshop

EVENTS/MEETINGS

October 24, 2006

BioShield Stakeholders Workshop

EVENTS/MEETINGS

April 07, 2004

NINDS Counterterrorism and Neuroscience Workshop

EVENTS/MEETINGS

February 09, 2004

NIAID Expert Panel on Botulinum Neurotoxins Therapeutics

EVENTS/MEETINGS

March 23, 2003

NIAID Expert Panel on Botulinum Diagnostics

EVENTS/MEETINGS

March 19, 2003

NIAID Expert Panel Review on Medical Chemical Defense

EVENTS/MEETINGS

November 20, 2002

NIAID Expert Panel on Botulinum Toxins

PRODUCTS

BARDA COVID-19 Medicalcountermeasure Products

PRODUCTS

BARDA Chemical, Biological, Radiological & Nuclear (CBRN) Products

PRODUCTS

BARDA DRIVe Products

Announcements & Media

EXPLORE ARTICLES

BARDA RESEARCH

Navigation

Resources

Popular

Social Media

I WANT TO FIND

Announcements & Media

Follow Us

EXPLORE ARTICLES

BARDA RESEARCH